Stereoselective hepatobiliary transport of the quinolone antibiotic grepafloxacin and its glucuronide in the rat.
A comparative pharmacokinetic study was performed for the optical isomers of grepafloxacin (GPFX), an asymmetric quinolone antibiotic. At steady state in rats receiving a constant infusion of each epimer, R(+)-GPFX and S(-)-GPFX, no marked difference between epimers was observed in plasma concentrations or in biliary and urinary excretion rates. The 3-glucuronides of GPFX are diastereomers. The biliary clearance, defined by the liver concentration of the 3-glucuronide of R(+)-GPFX (R-GPFX-Glu), was twice that of the 3-glucuronide of S(-)-GPFX (S-GPFX-Glu). Marked ATP dependence was observed in the uptake of both R-GPFX-Glu and S-GPFX-Glu by bile canalicular membrane vesicles. The ATP-dependent uptake of R-GPFX-Glu was also greater than that of S-GPFX-Glu. Kinetic analysis of the uptake of these glucuronides by bile canalicular membrane vesicles indicated that the affinity (1/Km) of S-GPFX-Glu for the transporter was 1.7 times higher than that of R-GPFX-Glu, whereas the Vmax of R-GPFX-Glu was 2.9 times greater than that of S-GPFX-Glu. The uptake of both glucuronides was reduced in mutant strain Eisai-hyperbilirubinemia rats, which have a hereditary defect in the bile canalicular multispecific organic anion transport system. Both glucuronides inhibited the ATP-dependent uptake of DNP-SG, a typical substrate for the bile canalicular multispecific organic anion transport system in a concentration-dependent manner, with a Ki of 21.5 microM and 8.8 microM for R-GPFX-Glu and S-GPFX-Glu, respectively. These Ki values were comparable with the corresponding Michaelis-Menten constant values for their uptake (17.3 microM and 10.1 microM, respectively). It is concluded that a major part of the stereoselective transport of these glucuronides across the bile canalicular membrane is mediated by a transporter that is deficient in Eisai-hyperbilirubinemia rats-possibly by the bile canalicular multispecific organic anion transport system.
Sasabe
H
H
Faculty of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.
Kato
Y
Y
Tsuji
A
A
Sugiyama
Y
Y
D000818:Animals; D000890:Anti-Infective Agents / Q000378:metabolism; D001652:Bile Ducts / Q000378:metabolism*; D001693:Biological Transport, Active; D002462:Cell Membrane / Q000378:metabolism; D002474:Cell-Free System; D002478:Cells, Cultured; D024841:Fluoroquinolones; D005965:Glucuronates; D006932:Hyperbilirubinemia / Q000378:metabolism; D007700:Kinetics; D008099:Liver / Q000378:metabolism*; D008297:Male; D010879:Piperazines / Q000378:metabolism*; D015363:Quinolones / Q000378:metabolism*; D051381:Rats; D011922:Rats, Mutant Strains / Q000378:metabolism; D017207:Rats, Sprague-Dawley; D013237:Stereoisomerism
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D005965:Glucuronates; D010879:Piperazines; D015363:Quinolones; C075375:grepafloxacin